Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial

2023; European Association of Percutaneous Cardiovascular Interventions; Volume: 19; Issue: 4 Linguagem: Inglês

10.4244/eij-d-23-00125

1969-6213

Patrícia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Fábio Serra Silveira, Murillo de Oliveira Antunes, Ricardo Reinaldo Bergo, Rodrigo M Joaquim, Jessica C S Hirai, Pedro Beraldo de Andrade, Fábio Grunspun Pitta, José Mariani, Bruno Ramos Nascimento, João Eduardo Tinoco de Paula, Marcos S. Silveira, Tiberio A O Costa, Frederico Toledo Campo Dall’Orto, Renato G Serpa, Fernanda B A Sampaio, Louis N Ohe, Fernanda Mangione, Remo H.M. Furtado, Rogério Sarmento‐Leite, Frederico Monfardini, Silvia Regina Lamas Assis, José Carlos Nicolau, Andrei C. Spósito, Renato D. Lópes, Yoshinobu Onuma, Marco Valgimigli, Dominick J. Angiolillo, Patrick W. Serruys, Otávio Berwanger, Fernando Bacal, Pedro A. Lemos,

Venous Thromboembolism Diagnosis and Management

Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y